Atul Pande

Atul Pande, listed as board member, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Immunovant, Inc. and Karuna Therapeutics, Inc. Over a trading history stretching from 1 April 2021 to 28 August 2026, the count stands at 28 filings.

Both buying and selling appear: 2 purchases worth €119k, against 5 sales worth €465k. The totals exclude 1 filing filed without an amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 7 share grants and 13 option exercises. Since January 2026: no purchases and 3 sales on the market.

On 28 August 2026 came the latest disclosure, an option exercise for €11k in Immunovant, Inc. The most recent open-market purchase was published on 4 October 2022, 1,475 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.